WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding an anti-PD-LI antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain and a light chain variable region sequence, wherein:

(a) the heavy chain comprises an HVR-H1, HVR-H2 and HVR-H3, wherein further:

(i) the HVR-H1 sequence is GFTFSDSWIH (SEQ ID NO: 15);

(ii) the HVR-H2 sequence is AWISPYGGSTYYADSVKG (SEQ ID NO: 16);

(iii) the HVR-H3 sequence is RHWPGGFDY (SEQ ID NO:3); and

(b) the light chain comprises an HVR-L1, HVR-L2 and HVR-L3, wherein further:

(iv) the HVR-L1 sequence is RASQDVSTAVA (SEQ ID NO: 17);

(v) the HVR-L2 sequence is SASFLYS (SEQ ID NO: 18);

(vi) the HVR-L3 sequence is QQYLYHPAT (SEQ ID NO: 19).

2. The nucleic acid of Claim 1, wherein the heavy chain variable region comprises framework sequences juxtaposed between the HVRs according to the formula: (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4).

3. The nucleic acid of claim 2, wherein the framework sequences are derived from human consensus framework sequences.

4. The nucleic acid of Claim 3, wherein the framework sequences are VH subgroup III consensus framework.

5. The nucleic acid of Claim 3, wherein one or more of the framework sequences is the following:

HC-FRl is EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4);

HC-FR2 is WVRQAPGKGLEWV (SEQ ID NO:5);

HC-FR3 is RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6);

HC-FR4 is WGQGTLVTVSA (SEQ ID NO:7).

6. The nucleic acid of 1, wherein the light chain variable region comprises framework sequences juxtaposed between the HVRs according to the formula: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4).

7. The nucleic acid of Claim 6 wherein the variable region light chain framework sequences are VL kappa I consensus framework.

8. The nucleic acid of Claim 7 wherein one or more of the framework sequences is the following:

LC-FR1 is DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 11);
LC-FR2 is WYQQKPGKAPKLLIY (SEQ ID NO: 12);
LC-FR3 is GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC, and (SEQ ID NO:13);
LC-FR4 is FGQGTKVEIKR (SEQ ID NO:14).

9. The nucleic acid of Claim 1 wherein the antibody or antigen binding fragment thereof comprises:

(a) variable region heavy chain framework sequences juxtaposed between the HVRs according to the formula: (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and

(b) variable region light chain framework sequences juxtaposed between the HVRs according to the formula: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4),

wherein the variable heavy chain framework sequences are the following:
(i) HC-FR1 is EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4);
(ii) HC-FR2 is WVRQAPGKGLEWV (SEQ ID NO:5);
(iii) HC-FR3 is RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6);
(iv) HC-FR4 is WGQGTLVTVSA (SEQ ID NO:7); and
further wherein the variable light chain framework sequences are the following:
(i) LC-FR1 is DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 11);
(ii) LC-FR2 is WYQQKPGKAPKLLIY (SEQ ID NO:12);
(iii) LC-FR3 is GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13);
(iv) LC-FR4 is FGQGTKVEIKR (SEQ ID N0:14).

10. The nucleic acid of Claim 9, wherein the antibody or antigen binding fragment thereof further comprises a human constant region.

11. The nucleic acid of Claim 10, wherein the constant region is selected from the group consisting of an IgG1 constant region, IgG2 constant region, IgG3 constant region and IgG4 constant region.

12. The nucleic acid of Claim 11, wherein the constant region is an IgG1 constant region.

13. The nucleic acid of Claim 12, wherein the antibody or antigen binding fragment thereof has reduced or minimal effector function.

14. The nucleic acid of Claim 13, wherein the minimal effector function results from an effector-less Fc mutation.

15. The nucleic acid of Claim 14, wherein the effector-less Fc mutation is N297A.

16. The nucleic acid of Claim 14, wherein the effector-less Fc mutation is D265A/N297A.

17. The nucleic acid of Claim 13, wherein the minimal effector function results from aglycosylation.

18. The nucleic acid of Claim 9, wherein the antibody or antigen binding fragment thereof further comprises a murine constant region.

19. The nucleic acid of Claim 18, wherein the constant region is selected from the group consisting of an IgG1 constant region, IgG2A constant region, IgG2B constant region and IgG3 constant region.

20. The nucleic acid of Claim 19, wherein the constant region is an IgG2A constant region.

21. The nucleic acid of Claim 20, wherein the antibody or antigen binding fragment thereof has reduced or minimal effector function.

22. The nucleic acid of Claim 21, wherein the minimal effector function results from an effector-less Fc mutation.

23. The nucleic acid of Claim 22, wherein the effector-less Fc mutation is N297A.

24. The nucleic acid of Claim 22, wherein the effector-less Fc mutation is D265A/N297A.

25. The nucleic acid of Claim 21, wherein the minimal effector function results from aglycosylation.

26. An isolated nucleic acid encoding an anti-PD-L1 antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain and light chain variable region sequence, wherein:

(a) the heavy chain comprises the sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISP
YGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFD
YWGQGTLVTVSA (SEQ ID NO:20), and
(b) the light chain comprises the sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVA
WYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ
YLYH PATFGQGTKVEIKR (SEQ ID NO:21).

27. The nucleic acid of Claim 26, wherein the antibody or antigen binding fragment thereof further comprises a human constant region.

28. The nucleic acid of Claim 27, wherein the constant region is selected from the group consisting of an IgG1 constant region, IgG2 constant region, IgG3 constant region and IgG4 constant region.

29. The nucleic acid of Claim 28, wherein the constant region is an IgG1 constant region.

30. The nucleic acid of Claim 29, wherein the antibody or antigen binding fragment thereof has reduced or minimal effector function.

31. The nucleic acid of Claim 30, wherein the minimal effector function results from an effector-less Fc mutation.

32. The nucleic acid of Claim 31, wherein the effector-less Fc mutation is N297A.

33. The nucleic acid of Claim 31, wherein the effector-less Fc mutation is D265A/N297A.

34. The nucleic acid of Claim 30, wherein the minimal effector function results from aglycosylation.

35. A vector comprising the nucleic acid of any of Claims 1-25.

36. A vector comprising the nucleic acid of any of Claims 26-34.

37. A host cell comprising the vector of Claim 35.

38. A host cell comprising the vector of Claim 36.

39. The host cell of Claim 37, which is eukaryotic.

40. The host cell of Claim 39, which is mammalian.

41. The host cell of Claim 40, which is a Chinese Hamster Ovary (CHO) cells.

42. The host cell of Claim 37, which is prokaryotic.

43. The host cell of Claim 42, which is *E. coli.*

44. A process for making an anti-PD-L1 antibody or antigen binding fragment thereof comprising culturing the host cell of Claim 41 under conditions suitable for the expression of the vector encoding the anti-PD-L1 antibody or antigen binding fragment thereof, and recovering the antibody or fragment.